查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1477401

胃肠道出血治疗市场 - 全球产业规模、份额、趋势、机会和预测，按产品、胃肠道部门、最终用户、地区和竞争细分，2019-2029F

Gastrointestinal Bleeding Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By GI Tract Division, By End Users, By Region, and By Competition, 2019-2029F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2023年全球胃肠道出血治疗市场价值为5.5767亿美元，预计到2029年将在预测期内实现稳定增长，复合年增长率为5.81%。和介入策略消化道内，包括食道、胃、小肠、大肠（结肠）、直肠和肛门。胃肠道出血可表现为上消化道出血（UGIB）（起源于消化系统的上部）或下消化道出血（LGIB）（起源于消化系统的下部）。患有急性胃肠道出血的患者可能需要立即復苏和稳定病情，以解决血流动力学不稳定问题，恢復液体和电解质平衡，并优化氧合和组织灌注。

市场概况
预测期 2025-2029
2023 年市场规模 5.5767亿美元
2029 年市场规模 77184万美元
2024-2029 年复合年增长率 5.81%
成长最快的细分市场 上消化道
最大的市场 北美洲

进行上消化道内视镜检查、大肠镜检查、胶囊内视镜检查和影像学检查（例如CT 血管摄影、核子医学扫描）等诊断测试，以确定胃肠道出血的来源、部位和严重程度，并指导后续的治疗决策。药物介入可用于控制胃肠道出血，包括使用质子帮浦抑制剂（PPI）减少胃酸分泌，使用抗生素根除幽门螺旋桿菌感染，使用血管活性药物控制出血，以及使用止血剂促进血块形成和止血。可以进行内视镜手术，例如热凝、注射硬化疗法、套扎、止血夹应用和氩气等离子凝固，以实现止血并控制溃疡、静脉曲张、动静脉畸形（AVM）和胃肠道内其他病变的出血。

消化性溃疡、发炎性肠道疾病（IBD）、大肠直肠癌、憩室病和血管异常等胃肠道疾病的盛行率不断增加，增加了对胃肠道出血治疗的需求。随着这些疾病的发生率在全球范围内上升，对胃肠道出血有效治疗方案的需求也随之增加。医疗技术的进步，特别是内视镜成像、介入放射学和外科技术的进步，扩大了消化道出血的治疗选择。新技术使医疗保健提供者能够更准确、更有效地诊断和治疗胃肠道出血，改善患者的治疗效果并降低併发症的风险。

人们对胃肠道疾病的认识不断提高，以及早期发现和治疗的重要性，导致大肠癌等疾病筛检计画的实施。筛检计画有助于识别有胃肠道出血风险的个体，并实现早期干预，改善患者的治疗结果并降低与晚期疾病阶段相关的医疗费用。

主要市场驱动因素

胃肠道疾病盛行率上升

提高认识和筛检计划

技术进步

主要市场挑战

治疗费用高

併发症的风险

主要市场趋势

生物疗法的需求不断增长

细分市场洞察

胃肠道部门的见解

最终使用者见解

区域洞察

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：客户之声

第 5 章：全球胃肠出血治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按产品（内视镜止血装置、闭合装置、其他）
    • 依胃肠道划分（上胃肠道、下胃肠道）
    • 最终使用者（医院/诊所、门诊手术中心、其他）
    • 按地区
    • 按公司划分 (2023)
  • 市场地图

第 6 章：北美胃肠出血治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按产品分类
    • 胃肠道部门
    • 由最终用户
    • 按国家/地区
  • 北美：国家分析
    • 美国
    • 加拿大
    • 墨西哥

第 7 章：欧洲胃肠出血治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按产品分类
    • 胃肠道部门
    • 由最终用户
    • 按国家/地区
  • 欧洲：国家分析
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙

第 8 章：亚太地区胃肠出血治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按产品分类
    • 胃肠道部门
    • 由最终用户
    • 按国家/地区
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第 9 章：南美洲胃肠出血治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按产品分类
    • 胃肠道部门
    • 由最终用户
    • 按国家/地区
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 10 章：中东和非洲胃肠出血治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按产品分类
    • 胃肠道部门
    • 由最终用户
    • 按国家/地区
  • MEA：国家分析
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第 11 章：市场动态

  • 司机
  • 挑战

第 12 章：市场趋势与发展

  • 併购（如有）
  • 产品发布（如有）
  • 最近的发展

第 13 章：波特的五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 客户的力量
  • 替代产品的威胁

第14章：竞争格局

  • Boston Scientific Corporation
  • Olympus Corporation
  • CONMED Corporation
  • Ovesco Endoscopy AG
  • Erbe Elektromedizin GmbH
  • Steris Plc
  • US Medical Innovations, LLC.
  • Pfizer Inc.

第 15 章：策略建议

第16章调查会社について・免责事项

简介目录
Product Code: 24061

Global Gastrointestinal Bleeding Treatment Market was valued at USD 557.67 million in 2023 and are expected to achieve an steady growth in the forecast period at a CAGR of 5.81% through 2029. Gastrointestinal bleeding treatment refers to the management and intervention strategies employed to address bleeding that occurs within the digestive tract, which includes the esophagus, stomach, small intestine, large intestine (colon), rectum, and anus. Gastrointestinal bleeding can manifest as either upper gastrointestinal bleeding (UGIB), which originates from the upper part of the digestive system, or lower gastrointestinal bleeding (LGIB), which originates from the lower part of the digestive system. Patients presenting with acute gastrointestinal bleeding may require immediate resuscitation and stabilization to address hemodynamic instability, restore fluid and electrolyte balance, and optimize oxygenation and tissue perfusion.

Market Overview
Forecast Period2025-2029
Market Size 2023USD 557.67 Million
Market Size 2029USD 771.84 Million
CAGR 2024-20295.81%
Fastest Growing SegmentUpper GI Tract
Largest MarketNorth America

Diagnostic tests such as upper endoscopy, colonoscopy, capsule endoscopy, and imaging studies (e.g., CT angiography, nuclear medicine scans) are performed to identify the source, location, and severity of gastrointestinal bleeding and guide subsequent treatment decisions. Pharmacological interventions may be utilized to manage gastrointestinal bleeding, including the administration of proton pump inhibitors (PPIs) to reduce gastric acid secretion, antibiotics to eradicate Helicobacter pylori infection, vasoactive drugs to control bleeding, and hemostatic agents to promote clot formation and hemostasis. Endoscopic procedures, such as thermal coagulation, injection sclerotherapy, band ligation, hemostatic clip application, and argon plasma coagulation, may be performed to achieve hemostasis and control bleeding from ulcers, varices, arteriovenous malformations (AVMs), and other lesions within the gastrointestinal tract.

The increasing prevalence of gastrointestinal disorders such as peptic ulcers, inflammatory bowel disease (IBD), colorectal cancer, diverticular disease, and vascular abnormalities contributes to the demand for gastrointestinal bleeding treatment. As the incidence of these conditions rises globally, the need for effective treatment options for gastrointestinal bleeding also increases. Advances in medical technology, particularly in endoscopic imaging, interventional radiology, and surgical techniques, have expanded the treatment options available for gastrointestinal bleeding. New technologies enable healthcare providers to diagnose and treat gastrointestinal bleeding more accurately and effectively, improving patient outcomes and reducing the risk of complications.

Increased awareness of gastrointestinal disorders and the importance of early detection and treatment has led to the implementation of screening programs for conditions such as colorectal cancer. Screening programs help identify individuals at risk of gastrointestinal bleeding and enable early intervention, improving patient outcomes and reducing healthcare costs associated with advanced disease stages.

Key Market Drivers

Rising Prevalence of Gastrointestinal Disorders

Peptic ulcers are open sores that develop on the lining of the stomach, small intestine, or esophagus. They can result from infection with Helicobacter pylori bacteria, long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs), excessive alcohol consumption, and smoking. Peptic ulcers can cause bleeding, leading to gastrointestinal bleeding. Inflammatory bowel disease comprises conditions such as Crohn's disease and ulcerative colitis, which involve chronic inflammation of the digestive tract. Inflammatory bowel disease can lead to ulcers, fissures, and inflammation throughout the gastrointestinal tract, increasing the risk of gastrointestinal bleeding. Colorectal cancer refers to cancer that develops in the colon or rectum. It is one of the leading causes of cancer-related deaths worldwide. Colorectal cancer can cause bleeding from tumors or ulcerated areas within the colon or rectum, resulting in gastrointestinal bleeding.

Diverticular disease involves the formation of small pouches (diverticula) in the colon. Diverticulosis refers to the presence of diverticula without inflammation, while diverticulitis occurs when diverticula become inflamed or infected. In severe cases, diverticulitis can cause bleeding and lead to gastrointestinal bleeding. Abnormalities in blood vessels within the gastrointestinal tract, such as arteriovenous malformations (AVMs) and angiodysplasia, can predispose individuals to gastrointestinal bleeding. These vascular malformations may rupture or bleed spontaneously, leading to acute or chronic gastrointestinal bleeding. Gastritis refers to inflammation of the stomach lining, while esophagitis involves inflammation of the esophagus. Chronic gastritis and esophagitis can result from various factors, including infection with Helicobacter pylori, excessive alcohol consumption, and gastroesophageal reflux disease (GERD). Inflammation and erosion of the gastrointestinal mucosa in gastritis and esophagitis can lead to bleeding. This factor will help in the development of the Global Gastrointestinal Bleeding Treatment Market.

Increasing Awareness and Screening Programs

Awareness and screening programs increase public awareness of gastrointestinal disorders, their risk factors, and associated symptoms. By educating individuals about the signs and symptoms of gastrointestinal conditions such as colorectal cancer, inflammatory bowel disease (IBD), and peptic ulcers, these programs encourage early recognition of potential gastrointestinal bleeding and prompt individuals to seek medical evaluation and treatment. Awareness campaigns help reduce stigma associated with gastrointestinal symptoms and encourage individuals to overcome barriers to seeking medical care. By raising awareness about the importance of gastrointestinal health and promoting open discussions about digestive symptoms, these programs empower individuals to prioritize their health and seek timely medical attention for gastrointestinal bleeding and related concerns. Awareness and screening programs promote evidence-based screening guidelines for gastrointestinal disorders, such as colorectal cancer screening guidelines endorsed by medical societies and public health organizations. By disseminating information about recommended screening modalities, age-based screening recommendations, and risk factors for gastrointestinal bleeding, these programs encourage individuals to undergo appropriate screening tests and preventive measures to detect gastrointestinal disorders at an early stage.

Awareness and screening programs facilitate access to screening services by raising awareness about available screening options, facilitating referrals to healthcare providers, and providing information about screening locations and resources. By increasing access to screening services, particularly in underserved communities and populations with limited healthcare access, these programs help identify individuals at risk of gastrointestinal bleeding and facilitate timely referral for diagnostic evaluation and treatment. Awareness and screening programs empower patients to actively participate in their healthcare decisions and engage in preventive health behaviors. By promoting shared decision-making between patients and healthcare providers, these programs facilitate informed discussions about screening options, risk factors, and treatment considerations for gastrointestinal bleeding and related conditions. These programs provide healthcare providers with tools and resources to support patient education, counseling, and follow-up care for individuals undergoing screening and treatment for gastrointestinal disorders. This factor will pace up the demand of the Global Gastrointestinal Bleeding Treatment Market.

Technological Advancements

Endoscopic imaging technologies, such as high-definition and narrow-band imaging, have improved visualization of gastrointestinal lesions and bleeding sources. These technologies enhance the ability of gastroenterologists to detect subtle abnormalities and accurately localize bleeding sites during endoscopic procedures. Endoscopic hemostatic techniques have evolved with the development of various devices and methods for achieving hemostasis in gastrointestinal bleeding. These include hemostatic clips, thermal coagulation probes, injection therapy with sclerosants or hemostatic agents, and newer technologies like over-the-scope clips (OTSC) and hemostatic powders. These techniques allow for precise and effective control of bleeding lesions, reducing the need for invasive surgical interventions. Capsule endoscopy involves the ingestion of a small, wireless capsule camera that captures images of the gastrointestinal tract as it passes through the digestive system. Capsule endoscopy is particularly useful for evaluating obscure gastrointestinal bleeding, as it can visualize areas of the small intestine that are inaccessible to traditional endoscopic techniques. Double balloon enteroscopy enables deep intubation of the small intestine using a specialized endoscope with an overtube and balloon attachments. This technique allows for the visualization and treatment of lesions in the small intestine, including sources of obscure gastrointestinal bleeding.

Angiographic embolization is a minimally invasive procedure used to control gastrointestinal bleeding by selectively occluding blood vessels that supply bleeding lesions. Advanced imaging modalities, such as digital subtraction angiography (DSA), allow interventional radiologists to precisely identify and target bleeding vessels, leading to successful hemostasis while preserving surrounding tissue. Radiofrequency ablation is a technique that uses thermal energy to destroy abnormal tissue, such as precancerous lesions or dysplastic tissue associated with Barrett's esophagus. RFA can be used to treat gastrointestinal bleeding secondary to conditions like Barrett's esophagus and certain types of precancerous lesions. Hemostatic powders composed of biocompatible materials, such as hydrophilic polymers or mineral particles, can be applied endoscopically to bleeding lesions to achieve hemostasis. These powders adhere to the bleeding surface and promote clot formation, providing an effective means of controlling gastrointestinal bleeding, particularly in difficult-to-reach or high-risk areas. Wireless pH monitoring systems enable ambulatory monitoring of esophageal pH levels to evaluate gastroesophageal reflux disease (GERD) and assess the severity of esophageal mucosal injury. These systems utilize wireless pH capsules placed in the esophagus to record pH levels over a specified period, providing valuable diagnostic information for the management of GERD-related complications, including esophageal bleeding. This factor will accelerate the demand of the Global Gastrointestinal Bleeding Treatment Market.

Key Market Challenges

High Cost of Treatment

Gastrointestinal bleeding treatment often involves the use of advanced medical technology and equipment, including endoscopes, imaging systems, hemostatic devices, and surgical instruments. The high cost of acquiring, maintaining, and upgrading these technologies contributes to the overall cost of treatment. Gastrointestinal bleeding treatment may require the expertise of specialized healthcare providers, including gastroenterologists, interventional radiologists, and gastrointestinal surgeons. These specialists typically command higher fees for their services, contributing to the overall cost of treatment. The diagnostic workup for gastrointestinal bleeding may involve various imaging studies, laboratory tests, and endoscopic procedures to identify the underlying cause and location of bleeding.

These diagnostic procedures can incur substantial costs, especially when multiple tests and imaging modalities are necessary to achieve an accurate diagnosis. Therapeutic interventions for gastrointestinal bleeding, such as endoscopic hemostasis, angiographic embolization, and surgical procedures, can be costly due to the use of specialized equipment, disposable supplies, anesthesia, and operating room expenses. The complexity and duration of these interventions may further contribute to their cost. Pharmacological treatments for gastrointestinal bleeding, including proton pump inhibitors (PPIs), anticoagulants, and hemostatic agents, can be expensive, especially for patients requiring long-term or combination therapy. The cost of medications may vary based on factors such as brand name versus generic formulations, dosage regimens, and insurance coverage.

Risk of Complications

Many treatment modalities for gastrointestinal bleeding, such as endoscopic hemostasis, angiographic embolization, and surgical interventions, are invasive procedures that carry inherent risks of complications, including bleeding, perforation, infection, and adverse reactions to anesthesia or contrast agents. Patients with gastrointestinal bleeding often have underlying health conditions, such as cardiovascular disease, liver cirrhosis, renal insufficiency, or coagulopathies, which may increase the risk of complications during treatment. Pre-existing comorbidities can complicate the management of gastrointestinal bleeding and necessitate careful risk stratification and treatment planning.

Pharmacological treatments for gastrointestinal bleeding, including anticoagulants, antiplatelet agents, and nonsteroidal anti-inflammatory drugs (NSAIDs), carry the risk of side effects such as gastrointestinal ulcers, renal impairment, and increased bleeding risk. The use of these medications in combination with other therapies for gastrointestinal bleeding may heighten the risk of adverse events and treatment-related complications. Individual patient factors, such as age, comorbidities, nutritional status, medication history, and adherence to treatment regimens, can influence the risk of complications during gastrointestinal bleeding treatment. Elderly patients and those with multiple medical conditions may be particularly vulnerable to treatment-related adverse events and may require tailored management approaches to mitigate risks.

Key Market Trends

Growing Demand of Biologic Therapies

Biologic therapies offer targeted approaches to gastrointestinal bleeding treatment by selectively inhibiting pro-inflammatory cytokines, immune mediators, and cell signaling pathways involved in the pathophysiology of gastrointestinal disorders. By modulating specific molecular targets, biologic agents can attenuate inflammation, promote mucosal healing, and mitigate the risk of gastrointestinal bleeding in conditions such as inflammatory bowel disease (IBD) and autoimmune gastritis. Clinical trials and real-world studies have demonstrated the efficacy and safety of biologic therapies in achieving and maintaining disease remission, reducing disease activity, and preventing disease complications in patients with gastrointestinal bleeding. Biologic agents such as anti-tumor necrosis factor (TNF) antibodies (e.g., infliximab, adalimumab) and anti-integrin antibodies (e.g., vedolizumab) have shown favorable outcomes in inducing and sustaining clinical and endoscopic remission in patients with IBD and reducing the risk of gastrointestinal bleeding-related hospitalizations and surgeries.

Biologic therapies have the potential to modify the natural history of gastrointestinal diseases by altering disease progression, preventing tissue damage, and modulating immune responses implicated in disease pathogenesis. By intervening early in the disease course, biologic agents may reduce the risk of long-term complications, including gastrointestinal bleeding, strictures, fistulas, and colorectal cancer, in patients with chronic inflammatory conditions affecting the gastrointestinal tract. The advent of personalized medicine approaches, including biomarker profiling, genetic testing, and pharmacogenomics, enables tailored selection of biologic therapies based on individual patient characteristics, disease phenotype, and treatment response. Personalized treatment algorithms help optimize therapeutic outcomes, minimize adverse effects, and enhance patient adherence to biologic therapy regimens in the management of gastrointestinal bleeding and related complications.

Segmental Insights

GI Tract Division Insights

The Lower GI Tract segment is projected to experience significant dominance in the Global Gastrointestinal Bleeding Treatment Market during the forecast period. Disorders affecting the lower gastrointestinal (GI) tract, including the colon, rectum, and anus, are common and can lead to gastrointestinal bleeding. Conditions such as diverticulosis, colorectal cancer, inflammatory bowel disease (IBD), and hemorrhoids contribute to the substantial burden of lower GI tract disorders globally. As the incidence and prevalence of these conditions rise, there is a greater demand for effective treatments to manage gastrointestinal bleeding originating from the lower GI tract. Advances in diagnostic technologies, such as colonoscopy, flexible sigmoidoscopy, and capsule endoscopy, have improved the detection and localization of sources of lower GI bleeding.

These technologies enable healthcare providers to accurately diagnose and assess the severity of lower GI tract disorders, facilitating targeted treatment interventions to control bleeding and prevent complications. Minimally invasive treatment options for lower GI tract bleeding, including endoscopic therapies such as thermal coagulation, injection therapy, and endoscopic clips, offer effective alternatives to traditional surgical approaches. These minimally invasive techniques are associated with reduced patient discomfort, shorter hospital stays, and faster recovery times, driving their adoption for the management of lower GI bleeding. The implementation of colorectal cancer screening programs and initiatives aimed at early detection and prevention of lower GI tract disorders has increased awareness and detection rates among at-risk populations. Screening programs help identify individuals with precancerous lesions or early-stage colorectal cancer, enabling timely intervention to prevent disease progression and reduce the risk of gastrointestinal bleeding-related complications.

End Users Insights

The Hospital/Clinics segment is projected to experience significant growth in the Global Gastrointestinal Bleeding Treatment Market during the forecast period. Hospitals and clinics serve as primary points of access for patients seeking medical care, including gastrointestinal bleeding treatment. As healthcare access improves globally, more individuals are likely to visit hospitals and clinics for diagnosis and treatment of gastrointestinal bleeding. Hospitals and clinics typically have advanced medical infrastructure, including endoscopy suites, interventional radiology facilities, and operating rooms equipped to perform complex procedures to diagnose and treat gastrointestinal bleeding effectively. The availability of such infrastructure enhances the capacity of hospitals and clinics to manage a wide range of gastrointestinal bleeding cases.

Gastrointestinal bleeding often requires a multidisciplinary approach involving gastroenterologists, interventional radiologists, surgeons, and other healthcare professionals. Hospitals and clinics provide an ideal setting for collaboration among specialists from different disciplines to develop comprehensive treatment plans tailored to individual patient needs. Many hospitals and clinics offer specialized services dedicated to the diagnosis and treatment of gastrointestinal disorders, including gastrointestinal bleeding. These specialized centers often have dedicated teams of healthcare professionals with expertise in managing various gastrointestinal conditions, ensuring high-quality care and optimal patient outcomes.

Regional Insights

North America emerged as the dominant region in the Global Gastrointestinal Bleeding Treatment Market in 2023. North America boasts highly developed healthcare infrastructure, including state-of-the-art hospitals, specialized treatment centers, and advanced medical technology. These facilities enable healthcare providers to offer a wide range of diagnostic and treatment options for gastrointestinal bleeding, including endoscopic procedures, interventional radiology, and surgical interventions. The region is at the forefront of technological innovation in healthcare, with ongoing advancements in diagnostic imaging, endoscopic devices, and therapeutic interventions for gastrointestinal bleeding. These technological innovations improve the accuracy of diagnosis, enhance treatment outcomes, and contribute to the overall quality of patient care.

North America is home to a large pool of skilled healthcare professionals, including gastroenterologists, interventional radiologists, surgeons, and nurses, who specialize in the diagnosis and treatment of gastrointestinal disorders. The expertise of these healthcare professionals contributes to the delivery of high-quality care and the effective management of gastrointestinal bleeding cases. The region benefits from robust investment in research and development (R&D) initiatives aimed at advancing medical knowledge, developing new treatment modalities, and improving patient outcomes in gastrointestinal bleeding management. Academic institutions, healthcare organizations, and industry stakeholders collaborate to drive innovation and translate scientific discoveries into clinical practice.

Key Market Players

Boston Scientific Corporation

Olympus Corporation

CONMED Corporation

Ovesco Endoscopy AG

Erbe Elektromedizin GmbH

Steris Plc

US Medical Innovations, LLC.

Pfizer Inc.

Report Scope:

In this report, the Global Gastrointestinal Bleeding Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Gastrointestinal Bleeding Treatment Market, By Product:

    Closure Devices Endoscopic Hemostatic Devices

Thermal Devices

Mechanical Devices

    Others

Gastrointestinal Bleeding Treatment Market, By GI Tract Division:

    Upper GI Tract Lower GI Tract

Gastrointestinal Bleeding Treatment Market, By End Users:

    Hospital/Clinics Ambulatory Surgical Centres Others

Gastrointestinal Bleeding Treatment Market, By Region:

    North America

United States

Canada

Mexico

    Europe

Germany

United Kingdom

France

Italy

Spain

    Asia-Pacific

China

Japan

India

Australia

South Korea

    South America

Brazil

Argentina

Colombia

    Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Gastrointestinal Bleeding Treatment Market.

Available Customizations:

Global Gastrointestinal Bleeding Treatment market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Gastrointestinal Bleeding Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Endoscopic Hemostatic Devices, Closure Devices, Others)
      • 5.2.1.1. By Endoscopic Hemostatic Devices (Thermal Devices, Mechanical Devices)
    • 5.2.2. By GI Tract Division (Upper GI Tract, Lower GI Tract)
    • 5.2.3. By End Users (Hospital/Clinics, Ambulatory Surgical Centres, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2023)
  • 5.3. Market Map

6. North America Gastrointestinal Bleeding Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By GI Tract Division
    • 6.2.3. By End Users
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Gastrointestinal Bleeding Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By GI Tract Division
        • 6.3.1.2.3. By End Users
    • 6.3.2. Canada Gastrointestinal Bleeding Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By GI Tract Division
        • 6.3.2.2.3. By End Users
    • 6.3.3. Mexico Gastrointestinal Bleeding Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By GI Tract Division
        • 6.3.3.2.3. By End Users

7. Europe Gastrointestinal Bleeding Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By GI Tract Division
    • 7.2.3. By End Users
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Gastrointestinal Bleeding Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By GI Tract Division
        • 7.3.1.2.3. By End Users
    • 7.3.2. United Kingdom Gastrointestinal Bleeding Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By GI Tract Division
        • 7.3.2.2.3. By End Users
    • 7.3.3. Italy Gastrointestinal Bleeding Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By GI Tract Division
        • 7.3.3.2.3. By End Users
    • 7.3.4. France Gastrointestinal Bleeding Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By GI Tract Division
        • 7.3.4.2.3. By End Users
    • 7.3.5. Spain Gastrointestinal Bleeding Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By GI Tract Division
        • 7.3.5.2.3. By End Users

8. Asia-Pacific Gastrointestinal Bleeding Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By GI Tract Division
    • 8.2.3. By End Users
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Gastrointestinal Bleeding Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By GI Tract Division
        • 8.3.1.2.3. By End Users
    • 8.3.2. India Gastrointestinal Bleeding Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By GI Tract Division
        • 8.3.2.2.3. By End Users
    • 8.3.3. Japan Gastrointestinal Bleeding Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By GI Tract Division
        • 8.3.3.2.3. By End Users
    • 8.3.4. South Korea Gastrointestinal Bleeding Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By GI Tract Division
        • 8.3.4.2.3. By End Users
    • 8.3.5. Australia Gastrointestinal Bleeding Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By GI Tract Division
        • 8.3.5.2.3. By End Users

9. South America Gastrointestinal Bleeding Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By GI Tract Division
    • 9.2.3. By End Users
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Gastrointestinal Bleeding Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By GI Tract Division
        • 9.3.1.2.3. By End Users
    • 9.3.2. Argentina Gastrointestinal Bleeding Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By GI Tract Division
        • 9.3.2.2.3. By End Users
    • 9.3.3. Colombia Gastrointestinal Bleeding Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By GI Tract Division
        • 9.3.3.2.3. By End Users

10. Middle East and Africa Gastrointestinal Bleeding Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By GI Tract Division
    • 10.2.3. By End Users
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Gastrointestinal Bleeding Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By GI Tract Division
        • 10.3.1.2.3. By End Users
    • 10.3.2. Saudi Arabia Gastrointestinal Bleeding Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By GI Tract Division
        • 10.3.2.2.3. By End Users
    • 10.3.3. UAE Gastrointestinal Bleeding Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By GI Tract Division
        • 10.3.3.2.3. By End Users

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Product

14. Competitive Landscape

  • 14.1. Boston Scientific Corporation
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As Reported)
    • 14.1.5. Recent Developments
    • 14.1.6. Key Personnel Details
    • 14.1.7. SWOT Analysis
  • 14.2. Olympus Corporation
  • 14.3. CONMED Corporation
  • 14.4. Ovesco Endoscopy AG
  • 14.5. Erbe Elektromedizin GmbH
  • 14.6. Steris Plc
  • 14.7. US Medical Innovations, LLC.
  • 14.8. Pfizer Inc.

15. Strategic Recommendations

16. About Us & Disclaimer